#BEGIN_DRUGCARD DB02032

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C9H15NO3S

# Chemical_IUPAC_Name:
(2S)-1-[(2R)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid

# HET_ID:
MCO

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7-/m0/s1

# InChI_Key:
InChIKey=FAKRSMQSSFJEIM-BQBZGAKWSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
2032

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
217.285

# Molecular_Weight_Mono:
217.077264041

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1JT1

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
1.02

# Predicted_LogS:
-1.7

# Predicted_Water_Solubility:
4.52e+00 g/l

# Primary_Accession_No:
DB02032

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
688267

# PubChem_Substance_ID:
46505775

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02137

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@](C)(CS)C(=O)N1CCC[C@@]1([H])C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:44 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cell membrane
single-pass type I membrane protein. Processed form:Secreted protein. A soluble form

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
ACE

# Drug_Target_1_GenBank_ID_Gene:
J04144

# Drug_Target_1_GenBank_ID_Protein:
178286

# Drug_Target_1_GeneCard_ID:
ACE

# Drug_Target_1_Gene_Name:
ACE

# Drug_Target_1_Gene_Sequence:
>3921 bp
ATGGGGGCCGCCTCGGGCCGCCGGGGGCCGGGGCTGCTGCTGCCGCTGCCGCTGCTGTTG
CTGCTGCCGCCGCAGCCCGCCCTGGCGTTGGACCCCGGGCTGCAGCCCGGCAACTTTTCT
GCTGACGAGGCCGGGGCGCAGCTCTTCGCGCAGAGCTACAACTCCAGCGCCGAACAGGTG
CTGTTCCAGAGCGTGGCCGCCAGCTGGGCGCACGACACCAACATCACCGCGGAGAATGCA
AGGCGCCAGGAGGAAGCAGCCCTGCTCAGCCAGGAGTTTGCGGAGGCCTGGGGCCAGAAG
GCCAAGGAGCTGTATGAACCGATCTGGCAGAACTTCACGGACCCGCAGCTGCGCAGGATC
ATCGGAGCTGTGCGAACCCTGGGCTCTGCCAACCTGCCCCTGGCTAAGCGGCAGCAGTAC
AACGCCCTGCTAAGCAACATGAGCAGGATCTACTCCACCGCCAAGGTCTGCCTCCCCAAC
AAGACTGCCACCTGCTGGTCCCTGGACCCAGATCTCACCAACATCCTGGCTTCCTCGCGA
AGCTACGCCATGCTCCTGTTTGCCTGGGAGGGCTGGCACAACGCTGCGGGCATCCCGCTG
AAACCGCTGTACGAGGATTTCACTGCCCTCAGCAATGAAGCCTACAAGCAGGACGGCTTC
ACAGACACGGGGGCCTACTGGCGCTCCTGGTACAACTCCCCCACCTTCGAGGACGATCTG
GAACACCTCTACCAACAGCTAGAGCCCCTCTACCTGAACCTCCATGCCTTCGTCCGCCGC
GCACTGCATCGCCGATACGGAGACAGATACATCAACCTCAGGGGACCCATCCCTGCTCAT
CTGCTGGGAGACATGTGGGCCCAGAGCTGGGAAAACATCTACGACATGGTGGTGCCTTTC
CCAGACAAGCCCAACCTCGATGTCACCAGTACTATGCTGCAGCAGGGCTGGAACGCCACG
CACATGTTCCGGGTGGCAGAGGAGTTCTTCACCTCCCTGGAGCTCTCCCCCATGCCTCCC
GAGTTCTGGGAAGGGTCGATGCTGGAGAAGCCGGCCGACGGGCGGGAAGTGGTGTGCCAC
GCCTCGGCTTGGGACTTCTACAACAGGAAAGACTTCAGGATCAAGCAGTGCACACGGGTC
ACGATGGACCAGCTCTCCACAGTGCACCATGAGATGGGCCATATACAGTACTACCTGCAG
TACAAGGATCTGCCCGTCTCCCTGCGTCGGGGGGCCAACCCCGGCTTCCATGAGGCCATT
GGGGACGTGCTGGCGCTCTCGGTCTCCACTCCTGAACATCTGCACAAAATCGGCCTGCTG
GACCGTGTCACCAATGACACGGAAAGTGACATCAATTACTTGCTAAAAATGGCACTGGAA
AAAATTGCCTTCCTGCCCTTTGGCTACTTGGTGGACCAGTGGCGCTGGGGGGTCTTTAGT
GGGCGTACCCCCCCTTCCCGCTACAACTTCGACTGGTGGTATCTTCGAACCAAGTATCAG
GGGATCTGTCCTCCTGTTACCCGAAACGAAACCCACTTTGATGCTGGAGCTAAGTTTCAT
GTTCCAAATGTGACACCATACATCAGGTACTTTGTGAGTTTTGTCCTGCAGTTCCAGTTC
CATGAAGCCCTGTGCAAGGAGGCAGGCTATGAGGGCCCACTGCACCAGTGTGACATCTAC
CGGTCCACCAAGGCAGGGGCCAAGCTCCGGAAGGTGCTGCAGGCTGGCTCCTCCAGGCCC
TGGCAGGAGGTGCTGAAGGACATGGTCGGCTTAGATGCCCTGGATGCCCAGCCGCTGCTC
AAGTACTTCCAGCCAGTCACCCAGTGGCTGCAGGAGCAGAACCAGCAGAACGGCGAGGTC
CTGGGCTGGCCCGAGTACCAGTGGCACCCGCCGTTGCCTGACAACTACCCGGAGGGCATA
GACCTGGTGACTGATGAGGCTGAGGCCAGCAAGTTTGTGGAGGAATATGACCGGACATCC
CAGGTGGTGTGGAACGAGTATGCCGAGGCCAACTGGAACTACAACACCAACATCACCACA
GAGACCAGCAAGATTCTGCTGCAGAAGAACATGCAAATAGCCAACCACACCCTGAAGTAC
GGCACCCAGGCCAGGAAGTTTGATGTGAACCAGTTGCAGAACACCACTATCAAGCGGATC
ATAAAGAAGGTTCAGGACCTAGAACGGGCAGCGCTGCCTGCCCAGGAGCTGGAGGAGTAC
AACAAGATCCTGTTGGATATGGAAACCACCTACAGCGTGGCCACTGTGTGCCACCCGAAT
GGCAGCTGCCTGCAGCTCGAGCCAGATCTGACGAATGTGATGGCCACATCCCGGAAATAT
GAAGACCTGTTATGGGCATGGGAGGGCTGGCGAGACAAGGCGGGGAGAGCCATCCTCCAG
TTTTACCCGAAATACGTGGAACTCATCAACCAGGCTGCCCGGCTCAATGGCTATGTAGAT
GCAGGGGACTCGTGGAGGTCTATGTACGAGACACCATCCCTGGAGCAAGACCTGGAGCGG
CTCTTCCAGGAGCTGCAGCCACTCTACCTCAACCTGCATGCCTACGTGCGCCGGGCCCTG
CACCGTCACTACGGGGCCCAGCACATCAACCTGGAGGGGCCCATTCCTGCTCACCTGCTG
GGGAACATGTGGGCGCAGACCTGGTCCAACATCTATGACTTGGTGGTGCCCTTCCCTTCA
GCCCCCTCGATGGACACCACAGAGGCTATGCTAAAGCAGGGCTGGACGCCCAGGAGGATG
TTTAAGGAGGCTGATGATTTCTTCACCTCCCTGGGGCTGCTGCCCGTGCCTCCTGAGTTC
TGGAACAAGTCGATGCTGGAGAAGCCAACCGACGGGCGGGAGGTGGTCTGCCACGCCTCG
GCCTGGGACTTCTACAACGGCAAGGACTTCCGGATCAAGCAGTGCACCACCGTGAACTTG
GAGGACCTGGTGGTGGCCCACCACGAAATGGGCCACATCCAGTATTTCATGCAGTACAAA
GACTTACCTGTGGCCTTGAGGGAGGGTGCCAACCCCGGCTTCCATGAGGCCATTGGGGAC
GTGCTAGCCCTCTCAGTGTCTACGCCCAAGCACCTGCACAGTCTCAACCTGCTGAGCAGT
GAGGGTGGCAGCGACGAGCATGACATCAACTTTCTGATGAAGATGGCCCTTGACAAGATC
GCCTTTATCCCCTTCAGCTACCTCGTCGATCAGTGGCGCTGGAGGGTATTTGATGGAAGC
ATCACCAAGGAGAACTATAACCAGGAGTGGTGGAGCCTCAGGCTGAAGTACCAGGGCCTC
TGCCCCCCAGTGCCCAGGACTCAAGGTGACTTTGACCCAGGGGCCAAGTTCCACATTCCT
TCTAGCGTGCCTTACATCAGGTACTTTGTCAGCTTCATCATCCAGTTCCAGTTCCACGAG
GCACTGTGCCAGGCAGCTGGCCACACGGGCCCCCTGCACAAGTGTGACATCTACCAGTCC
AAGGAGGCCGGGCAGCGCCTGGCGACCGCCATGAAGCTGGGCTTCAGTAGGCCGTGGCCG
GAAGCCATGCAGCTGATCACGGGCCAGCCCAACATGAGCGCCTCGGCCATGTTGAGCTAC
TTCAAGCCGCTGCTGGACTGGCTCCGCACGGAGAACGAGCTGCATGGGGAGAAGCTGGGC
TGGCCGCAGTACAACTGGACGCCGAACTCCGCTCGCTCAGAAGGGCCCCTCCCAGACAGC
GGCCGCGTCAGCTTCCTGGGCCTGGACCTGGATGCGCAGCAGGCCCGCGTGGGCCAGTGG
CTGCTGCTCTTCCTGGGCATCGCCCTGCTGGTAGCCACCCTGGGCCTCAGCCAGCGGCTC
TTCAGCATCCGCCACCGCAGCCTCCACCGGCACTCCCACGGGCCCCAGTTCGGCTCCGAG
GTGGAGCTGAGACACTCCTGA

# Drug_Target_1_General_Function:
Involved in metallopeptidase activity

# Drug_Target_1_General_References:
10319862	Rieder MJ, Taylor SL, Clark AG, Nickerson DA: Sequence variation in the human angiotensin converting enzyme. Nat Genet. 1999 May;22(1):59-62.
10391210	Halushka MK, Fan JB, Bentley K, Hsie L, Shen N, Weder A, Cooper R, Lipshutz R, Chakravarti A: Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nat Genet. 1999 Jul;22(3):239-47.
10924499	Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ: A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000 Oct 27;275(43):33238-43.
10969042	Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S: A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000 Sep 1;87(5):E1-9.
12459472	Harmer D, Gilbert M, Borman R, Clark KL: Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett. 2002 Dec 4;532(1-2):107-10.
1649623	Ehlers MR, Riordan JF: Angiotensin-converting enzyme: zinc- and inhibitor-binding stoichiometries of the somatic and testis isozymes. Biochemistry. 1991 Jul 23;30(29):7118-26.
2558109	Takeuchi K, Shimizu T, Ohishi N, Seyama Y, Takaku F, Yotsumoto H: Purification of human lung angiotensin-converting enzyme by high-performance liquid chromatography: properties and N-terminal amino acid sequence. J Biochem (Tokyo). 1989 Sep;106(3):442-5.
2849100	Soubrier F, Alhenc-Gelas F, Hubert C, Allegrini J, John M, Tregear G, Corvol P: Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc Natl Acad Sci U S A. 1988 Dec;85(24):9386-90.

# Drug_Target_1_HGNC_ID:
HGNC:2707

# Drug_Target_1_HPRD_ID:
00108

# Drug_Target_1_ID:
244

# Drug_Target_1_Locus:
17q23.3

# Drug_Target_1_Molecular_Weight:
149716

# Drug_Target_1_Name:
Angiotensin-converting enzyme

# Drug_Target_1_Number_of_Residues:
1306

# Drug_Target_1_PDB_ID:
1UZF

# Drug_Target_1_Pathway:
Benazepril Pathway	SMP00145
Captopril Pathway	SMP00146
Cilazapril Pathway	SMP00147
Enalapril Pathway	SMP00148
Fosinopril Pathway	SMP00149
Lisinopril Pathway	SMP00150
Moexipril Pathway	SMP00151
Perindopril Pathway	SMP00152
Quinapril Pathway	SMP00153
Ramipril Pathway	SMP00154
Rescinnamine Pathway	SMP00155
Spirapril Pathway	SMP00156
Trandolapril Pathway	SMP00157

# Drug_Target_1_Pfam_Domain_Function:
PF01401	Peptidase_M2

# Drug_Target_1_Protein_Sequence:
>Angiotensin-converting enzyme, somatic isoform precursor
MGAASGRRGPGLLLPLPLLLLLPPQPALALDPGLQPGNFSADEAGAQLFAQSYNSSAEQV
LFQSVAASWAHDTNITAENARRQEEAALLSQEFAEAWGQKAKELYEPIWQNFTDPQLRRI
IGAVRTLGSANLPLAKRQQYNALLSNMSRIYSTAKVCLPNKTATCWSLDPDLTNILASSR
SYAMLLFAWEGWHNAAGIPLKPLYEDFTALSNEAYKQDGFTDTGAYWRSWYNSPTFEDDL
EHLYQQLEPLYLNLHAFVRRALHRRYGDRYINLRGPIPAHLLGDMWAQSWENIYDMVVPF
PDKPNLDVTSTMLQQGWNATHMFRVAEEFFTSLELSPMPPEFWEGSMLEKPADGREVVCH
ASAWDFYNRKDFRIKQCTRVTMDQLSTVHHEMGHIQYYLQYKDLPVSLRRGANPGFHEAI
GDVLALSVSTPEHLHKIGLLDRVTNDTESDINYLLKMALEKIAFLPFGYLVDQWRWGVFS
GRTPPSRYNFDWWYLRTKYQGICPPVTRNETHFDAGAKFHVPNVTPYIRYFVSFVLQFQF
HEALCKEAGYEGPLHQCDIYRSTKAGAKLRKVLQAGSSRPWQEVLKDMVGLDALDAQPLL
KYFQPVTQWLQEQNQQNGEVLGWPEYQWHPPLPDNYPEGIDLVTDEAEASKFVEEYDRTS
QVVWNEYAEANWNYNTNITTETSKILLQKNMQIANHTLKYGTQARKFDVNQLQNTTIKRI
IKKVQDLERAALPAQELEEYNKILLDMETTYSVATVCHPNGSCLQLEPDLTNVMATSRKY
EDLLWAWEGWRDKAGRAILQFYPKYVELINQAARLNGYVDAGDSWRSMYETPSLEQDLER
LFQELQPLYLNLHAYVRRALHRHYGAQHINLEGPIPAHLLGNMWAQTWSNIYDLVVPFPS
APSMDTTEAMLKQGWTPRRMFKEADDFFTSLGLLPVPPEFWNKSMLEKPTDGREVVCHAS
AWDFYNGKDFRIKQCTTVNLEDLVVAHHEMGHIQYFMQYKDLPVALREGANPGFHEAIGD
VLALSVSTPKHLHSLNLLSSEGGSDEHDINFLMKMALDKIAFIPFSYLVDQWRWRVFDGS
ITKENYNQEWWSLRLKYQGLCPPVPRTQGDFDPGAKFHIPSSVPYIRYFVSFIIQFQFHE
ALCQAAGHTGPLHKCDIYQSKEAGQRLATAMKLGFSRPWPEAMQLITGQPNMSASAMLSY
FKPLLDWLRTENELHGEKLGWPQYNWTPNSARSEGPLPDSGRVSFLGLDLDAQQARVGQW
LLLFLGIALLVATLGLSQRLFSIRHRSLHRHSHGPQFGSEVELRHS

# Drug_Target_1_Reaction:
Release of a C-terminal dipeptide, oligopeptide!Xaa-Yaa, when Xaa is not Pro, and Yaa is neither Asp nor Glu. Thus, conversion of angiotensin I to angiotensin II, with increase in vasoconstrictor activity, but no action on angiotensin II COFACTOR Zinc INHIBITOR (S)-N-[3-(3,4-Methylenedioxyphenyl)-2-(mercaptomethyl)-1-oxoprolyl]g lycine; (S)-N-[3-(3,4-Methylenedioxyphenyl)-2-(mercaptomethyl)-1-oxoprolyl]- (S)-alanine; (S)-N-[3-(3,4-Methylenedioxyphenyl)-2-(acetylthio)methyl-1-oxoprolyl ]glycine benzyl ester; (S)-N-[3-(3,4-Methylenedioxyphenyl)-2-(acetylthio)methyl-1-oxoprolyl ]-(S)-alanine benzyl ester EFFECTOR Chloride

# Drug_Target_1_Signals:
1-29

# Drug_Target_1_Specific_Function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator

# Drug_Target_1_SwissProt_ID:
P12821

# Drug_Target_1_SwissProt_Name:
ACE_HUMAN

# Drug_Target_1_Synonyms:
Angiotensin-converting enzyme, somatic isoform precursor
CD143 antigen
Dipeptidyl carboxypeptidase I
EC 3.4.15.1
Kininase II

# Drug_Target_1_Theoretical_pI:
6.36

# Drug_Target_1_Transmembrane_Regions:
1260-1276

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
Y17896

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
blaFEZ-1

# Drug_Target_2_Gene_Sequence:
>849 bp
ATGAAAAAAGTATTAAGTTTAACCGCATTGATGATGGTATTGAACCATTCAAGCTTCGCA
TATCCAATGCCAAATCCTTTTCCCCCATTCCGTATTGCTGGAAACTTGTACTATGTAGGC
ACTGATGATCTCGCAAGCTACCTGATTGTCACACCGAGAGGGAACATTTTGATCAATAGT
GATCTTGAGGCTAATGTTCCCATGATTAAAGCAAGTATAAAAAAACTAGGTTTTAAATTC
AGTGATACTAAAATTTTGCTGATTAGCCATGCTCATTTTGATCATGCGGCCGGTAGCGAA
TTAATTAAGCAACAAACAAAAGCAAAATATATGGTTATGGACGAGGATGTTTCGGTGATC
CTGTCTGGCGGTAAATCTGATTTTCATTATGCTAATGATTCCAGTACTTATTTTACTCAG
AGTACTGTGGATAAGGTTCTTCACGACGGAGAACGGGTGGAATTAGGAGGGACCGTATTA
ACTGCTCATTTGACTCCTGGACACACTAGAGGCTGTACCACCTGGACAATGAAACTAAAA
GATCACGGCAAGCAATATCAGGCCGTAATTATAGGAAGTATTGGCGTAAATCCTGGGTAT
AAATTGGTTGATAATATAACTTATCCAAAAATTGCCGAAGATTATAAGCACTCCATAAAG
GTACTTGAGTCAATGCGTTGCGATATTTTTCTAGGATCGCATGCCGGAATGTTTGATCTG
AAGAATAAATATGTACTATTACAAAAAGGTCAAAACAATCCCTTTGTTGATCCCACAGGC
TGTAAAAATTATATTGAACAAAAGGCAAACGATTTTTACACAGAACTTAAGAAGCAAGAA
ACTGCCTAA

# Drug_Target_2_General_Function:
Involved in hydrolase activity

# Drug_Target_2_General_References:
10817705	Boschi L, Mercuri PS, Riccio ML, Amicosante G, Galleni M, Frere JM, Rossolini GM: The Legionella (Fluoribacter) gormanii metallo-beta-lactamase: a new member of the highly divergent lineage of molecular-subclass B3 beta-lactamases. Antimicrob Agents Chemother. 2000 Jun;44(6):1538-43.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
4586

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
31466

# Drug_Target_2_Name:
FEZ-1 protein

# Drug_Target_2_Number_of_Residues:
282

# Drug_Target_2_PDB_ID:
1K07

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00753	Lactamase_B

# Drug_Target_2_Protein_Sequence:
>FEZ-1 protein
MKKVLSLTALMMVLNHSSFAYPMPNPFPPFRIAGNLYYVGTDDLASYLIVTPRGNILINS
DLEANVPMIKASIKKLGFKFSDTKILLISHAHFDHAAGSELIKQQTKAKYMVMDEDVSVI
LSGGKSDFHYANDSSTYFTQSTVDKVLHDGERVELGGTVLTAHLTPGHTRGCTTWTMKLK
DHGKQYQAVIIGSIGVNPGYKLVDNITYPKIAEDYKHSIKVLESMRCDIFLGSHAGMFDL
KNKYVLLQKGQNNPFVDPTGCKNYIEQKANDFYTELKKQETA

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Not Available

# Drug_Target_2_SwissProt_ID:
Q9K578

# Drug_Target_2_SwissProt_Name:
Q9K578_9GAMM

# Drug_Target_2_Synonyms:
Not Available

# Drug_Target_2_Theoretical_pI:
8.68

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Cytoplasmic

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
X96858

# Drug_Target_3_GenBank_ID_Protein:
Not Available

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
blaB1

# Drug_Target_3_Gene_Sequence:
>750 bp
ATGTTGAAAAAAATAAAAATAAGCTTGATTCTTGCTCTTGGGCTTACCAGTTTGCAGGCA
TTTGGACAGGAGAATCCTGATGTCAAAATTGAAAAGCTAAAAGATAATCTGTATGTATAC
ACAACCTACAATACATTTAACGGGACTAAATATGCCGCAAATGCAGTATATCTGGTAACT
GATAAGGGTGTTGTGGTTATAGACTGTCCGTGGGGAGAAGACAAATTTAAAAGCTTTACG
GACGAGATTTATAAAAAACACGGAAAGAAAGTTATTATGAATATTGCAACACATTCTCAT
GATGATCGTGCCGGAGGTCTTGAATATTTTGGTAAAATAGGTGCAAAAACTTATTCTACT
AAAATGACAGATTCTATTTTAGCAAAAGAGAATAAGCCAAGAGCACAATATACTTTTGAC
AATAATAAATCTTTCAAAGTAGGAAAATCCGAGTTTCAGGTTTACTATCCCGGAAAAGGG
CACACAGCAGATAATGTGGTGGTATGGTTTCCAAAAGAAAAAGTATTGGTTGGAGGTTGT
ATTATAAAAAGTGCTGATTCAAAGGACCTGGGGTATATTGGAGAAGCATATGTAAACGAC
TGGACGCAGTCTGTACACAATATTCAACAAAAGTTTTCCGGTGCTCAGTACGTTGTTGCA
GGGCATGATGATTGGAAAGATCAAAGATCAATACAACATACACTAGACTTAATCAATGAA
TATCAACAAAAACAAAAGGCTTCAAATTAA

# Drug_Target_3_General_Function:
Involved in zinc ion binding

# Drug_Target_3_General_References:
10858348	Bellais S, Aubert D, Naas T, Nordmann P: Molecular and biochemical heterogeneity of class B carbapenem-hydrolyzing beta-lactamases in Chryseobacterium meningosepticum. Antimicrob Agents Chemother. 2000 Jul;44(7):1878-86.
9576862	Rossolini GM, Franceschini N, Riccio ML, Mercuri PS, Perilli M, Galleni M, Frere JM, Amicosante G: Characterization and sequence of the Chryseobacterium (Flavobacterium) meningosepticum carbapenemase: a new molecular class B beta-lactamase showing a broad substrate profile. Biochem J. 1998 May 15;332 ( Pt 1):145-52.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
4587

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
28144

# Drug_Target_3_Name:
Carbapenem-hydrolyzing beta-lactamase blaB-1

# Drug_Target_3_Number_of_Residues:
249

# Drug_Target_3_PDB_ID:
1M2X

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00753	Lactamase_B

# Drug_Target_3_Protein_Sequence:
>Carbapenem-hydrolyzing beta-lactamase blaB-1
MLKKIKISLILALGLTSLQAFGQENPDVKIEKLKDNLYVYTTYNTFNGTKYAANAVYLVT
DKGVVVIDCPWGEDKFKSFTDEIYKKHGKKVIMNIATHSHDDRAGGLEYFGKIGAKTYST
KMTDSILAKENKPRAQYTFDNNKSFKVGKSEFQVYYPGKGHTADNVVVWFPKEKVLVGGC
IIKSADSKDLGYIGEAYVNDWTQSVHNIQQKFSGAQYVVAGHDDWKDQRSIQHTLDLINE
YQQKQKASN

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
1-22

# Drug_Target_3_Specific_Function:
Hydrolyzes penicillins, cephalosporins (including cefoxitin), carbapenems and 6-beta-iodopenicillanate

# Drug_Target_3_SwissProt_ID:
O08498

# Drug_Target_3_SwissProt_Name:
BLAB1_FLAME

# Drug_Target_3_Synonyms:
CHbetaL-1
Carbapenem-hydrolyzing beta-lactamase blaB-1 precursor
Class B carbapenemase blaB-1
EC 3.5.2.6

# Drug_Target_3_Theoretical_pI:
9.36

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Periplasm (Potential)

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
X75074

# Drug_Target_4_GenBank_ID_Protein:
Not Available

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
Not Available

# Drug_Target_4_Gene_Sequence:
>873 bp
ATGCGTTCTACCCTGCTCGCCTTCGCCCTGGCCGTCGCTCTTCCGGCCGCCCACACCAGC
GCCGCCGAAGTACCACTGCCGCAGCTGCGGGCCTACACCGTGGACGCCTCGTGGCTGCAG
CCGATGGCACCGCTGCAGATCGCCGACCACACCTGGCAGATCGGCACCGAGGACCTGACC
GCGCTGCTTGTGCAGACCCCCGACGGCGCGGTGCTGCTCGACGGCGGCATGCCGCAGATG
GCCAGCCACCTGCTGGACAACATGAAGGCGCGTGGCGTGACGCCTCGGGATCTGCGGCTG
ATCCTGCTCAGCCACGCACACGCCGACCATGCCGGACCGGTGGCGGAGCTGAAGCGCCGT
ACGGGCGCCAAAGTGGCGGCCAACGCCGAATCGGCGGTGCTGCTGGCGCGTGGCGGCAGC
GATGACCTGCACTTCGGCGATGGCATCACCTACCCGCCTGCCAATGCAGACCGCATCGTC
ATGGATGGTGAAGTGATCACGGTGGGCGGCATCGTGTTCACCGCGCACTTCATGGCGGGG
CACACCCCGGGCAGCACCGCGTGGACCTGGACCGATACCCGCAATGGCAAGCCGGTGCGC
ATCGCCTACGCCGACAGCCTGAGTGCACCGGGCTACCAGCTGCAGGGAAACCCCCGTTAT
CCGCACCTGATCGAGGATTACAGGCGCAGCTTCGCGACGGTGCGGGCGCTGCCTTGCGAC
GTGTTGCTGACACCGCATCCGGGTGCCAGCAACTGGGACTACGCCGCGGGTGCCAGGGCC
GGTGCCAAGGCACTGACCTGCAAGGCCTACGCGGATGCGGCAGAACAGAAATTCGACGGG
CAGCTGGCCAAGGAAACGGCCGGGGCCCGCTGA

# Drug_Target_4_General_Function:
Involved in zinc ion binding

# Drug_Target_4_General_References:
3931629	Bicknell R, Emanuel EL, Gagnon J, Waley SG: The production and molecular properties of the zinc beta-lactamase of Pseudomonas maltophilia IID 1275. Biochem J. 1985 Aug 1;229(3):791-7.
8018721	Walsh TR, Hall L, Assinder SJ, Nichols WW, Cartwright SJ, MacGowan AP, Bennett PM: Sequence analysis of the L1 metallo-beta-lactamase from Xanthomonas maltophilia. Biochim Biophys Acta. 1994 Jun 21;1218(2):199-201.
9811546	Ullah JH, Walsh TR, Taylor IA, Emery DC, Verma CS, Gamblin SJ, Spencer J: The crystal structure of the L1 metallo-beta-lactamase from Stenotrophomonas maltophilia at 1.7 A resolution. J Mol Biol. 1998 Nov 20;284(1):125-36.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
5754

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
30801

# Drug_Target_4_Name:
Metallo-beta-lactamase L1

# Drug_Target_4_Number_of_Residues:
290

# Drug_Target_4_PDB_ID:
1SML

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00753	Lactamase_B

# Drug_Target_4_Protein_Sequence:
>Metallo-beta-lactamase L1
MRSTLLAFALAVALPAAHTSAAEVPLPQLRAYTVDASWLQPMAPLQIADHTWQIGTEDLT
ALLVQTPDGAVLLDGGMPQMASHLLDNMKARGVTPRDLRLILLSHAHADHAGPVAELKRR
TGAKVAANAESAVLLARGGSDDLHFGDGITYPPANADRIVMDGEVITVGGIVFTAHFMAG
HTPGSTAWTWTDTRNGKPVRIAYADSLSAPGYQLQGNPRYPHLIEDYRRSFATVRALPCD
VLLTPHPGASNWDYAAGARAGAKALTCKAYADAAEQKFDGQLAKETAGAR

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
1-21

# Drug_Target_4_Specific_Function:
Has a high activity against imipenem

# Drug_Target_4_SwissProt_ID:
P52700

# Drug_Target_4_SwissProt_Name:
BLA1_STEMA

# Drug_Target_4_Synonyms:
Beta-lactamase type II
EC 3.5.2.6
Metallo-beta-lactamase L1 precursor
Penicillinase

# Drug_Target_4_Theoretical_pI:
6.92

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Periplasm (Probable)

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_5_Essentiality:
Essential

# Drug_Target_5_GenAtlas_ID:
Not Available

# Drug_Target_5_GenBank_ID_Gene:
X57102

# Drug_Target_5_GenBank_ID_Protein:
38824

# Drug_Target_5_GeneCard_ID:
cphA

# Drug_Target_5_Gene_Name:
cphA

# Drug_Target_5_Gene_Sequence:
>765 bp
ATGATGAAAGGTTGGATGAAGTGTGGATTGGCCGGCGCCGTGGTGCTGATGGCGAGTTTC
TGGGGTGGCAGCGTGCGGGCGGCGGGGATGTCGCTGACGCAGGTGAGCGGCCCTGTGTAT
GTGGTAGAGGACAACTACTACGTGCAGGAAAATTCCATGGTCTATTTCGGGGCCAAGGGC
GTGACTGTGGTGGGGGCGACCTGGACGCCGGACACCGCCCGCGAGCTGCACAAGCTGATC
AAACGGGTCAGCCGCAAGCCGGTGCTGGAGGTGATCAACACCAACTACCACACCGACCGG
GCTGGCGGTAACGCCTACTGGAAGTCCATCGGTGCCAAGGTGGTGTCGACCCGCCAGACC
CGGGATCTGATGAAGAGCGACTGGGCCGAGATTGTTGCCTTTACCCGCAAGGGGCTGCCG
GAGTACCCGGATCTGCCGCTGGTGCTGCCCAACGTGGTGCACGATGGCGACTTCACGCTG
CAAGAGGGCAAGGTGCGCGCCTTCTACGCGGGCCCGGCCCATACGCCGGACGGCATCTTT
GTCTACTTCCCCGACGAGCAGGTGCTCTATGGCAACTGCATTCTCAAGGAGAAGCTGGGC
AACCTGAGCTTTGCCGATGTGAAGGCCTATCCACAGACGCTTGAGCGGCTGAAAGCGATG
AAGCTGCCGATCAAGACGGTGATCGGCGGTCACGACTCACCGCTGCACGGCCCCGAGCTG
ATTGATCACTACGAAGCGCTGATCAAGGCCGCACCCCAGTCATAA

# Drug_Target_5_General_Function:
Involved in beta-lactamase activity

# Drug_Target_5_General_References:
1856163	Massidda O, Rossolini GM, Satta G: The Aeromonas hydrophila cphA gene: molecular heterogeneity among class B metallo-beta-lactamases. J Bacteriol. 1991 Aug;173(15):4611-7.

# Drug_Target_5_HGNC_ID:
Not Available

# Drug_Target_5_HPRD_ID:
Not Available

# Drug_Target_5_ID:
6701

# Drug_Target_5_Locus:
Not Available

# Drug_Target_5_Molecular_Weight:
28016.2

# Drug_Target_5_Name:
Beta-lactamase

# Drug_Target_5_Number_of_Residues:
254

# Drug_Target_5_PDB_ID:
1X8G

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00753	Lactamase_B

# Drug_Target_5_Protein_Sequence:
>Beta-lactamase
MMKGWMKCGLAGAVVLMASFWGGSVRAAGMSLTQVSGPVYVVEDNYYVQENSMVYFGAKG
VTVVGATWTPDTARELHKLIKRVSRKPVLEVINTNYHTDRAGGNAYWKSIGAKVVSTRQT
RDLMKSDWAEIVAFTRKGLPEYPDLPLVLPNVVHDGDFTLQEGKVRAFYAGPAHTPDGIF
VYFPDEQVLYGNCILKEKLGNLSFADVKAYPQTLERLKAMKLPIKTVIGGHDSPLHGPEL
IDHYEALIKAAPQS

# Drug_Target_5_Reaction:
Not Available

# Drug_Target_5_Signals:
1-27

# Drug_Target_5_Specific_Function:
Can hydrolyze carbapenem compounds

# Drug_Target_5_SwissProt_ID:
P26918

# Drug_Target_5_SwissProt_Name:
BLAB_AERHY

# Drug_Target_5_Synonyms:
Not Available

# Drug_Target_5_Theoretical_pI:
8.90

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Not Available

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_6_Essentiality:
Essential

# Drug_Target_6_GenAtlas_ID:
Not Available

# Drug_Target_6_GenBank_ID_Gene:
AE003853

# Drug_Target_6_GenBank_ID_Protein:
9657379

# Drug_Target_6_GeneCard_ID:
Not Available

# Drug_Target_6_Gene_Name:
VC_A1006

# Drug_Target_6_Gene_Sequence:
>1977 bp
ATGAGCTCAGAAGAAAAACGATTGATCAAATTGCCAAGAACTCACAAAGATGGTCATCTT
TTTGAAGTCTCTGAAGCCGCGATTGACTGGATTGAACAGTATCAACACTTTAAAGGTGTC
ACGAAAAGCATTGTTGAACTTTTGAATCTGATCTCACTGCGTGGATTACGCAGTAGAGAT
GGCTTAGTTTCAACCACAGAACTGATTGATGCAACCGATGGGCAGCTGACGCGTGCAGCC
ATCCAGCAGCGCTTGAGAGCAGCGGTAGCTGTTGGATTGTTCAAACAAATCCCAGTGCGT
TTTGAAGAGGGGCTGGCTGGCAAAACCATGCTCCATCGTTTCATTAACCCCAACCAATTG
ATCTCGGTACTCGGCTCAACCAGCTTAGTCACTGAATCGGTTAAGCAAAATGAAAAGCAA
AAGCGCTCAAAAGCATTAGCGCAGACGCAAGTCAATCAACGTTTACTGCATGAGCATGGT
TTAAATACACCGCCAGCCATGAAAGATGAGGCTGATCAGTTTGTGGTCTCACCGACTAAC
TGGGCAGGGATCATTGATCAAGCGTTAGCGCCACCCAGAACCCGCAAGAGCTACCAAAAG
TCTATGGTTTCGATATCGGGTACTCGTGCTGTGATTGAAACACGATCGTCTAAAAACATC
ATGACGGTCGACGATCTGATGACTTTGTTTGCCTTATTCACTTTAACAGTGCAATACCAT
GATCATCACCAAGATGATTACCATTTCAATGCTAAACAAGCACCAAACAAAACGCCGCTG
TATATCACCGACATTCTCTCTTTACGTGGCAAAAAAGACAGCGGCCCGGCACGTGACTCG
ATCCGTGACAGTATTGATCGTATTGAATTTACCGATTTTCAGTTGCATGAACTGACGGGT
CGTTGGCTCAGTGAGAATATGCCAGAAGGCTTTAAAAGCGATCGTTTTCGCTTTTTAGCG
CGCACCATCACCGCTTCCGAAGAGGCACCTGTGGAAGGCAGTGATGGCGAGATCCGCATC
AAACCCAATCTGTACATTTTGGTGTGGGAGCCTTCGTTTTTTGAAGAGCTATTGACGCGA
GATTATTTCTTCCTATTTCCACCGGAGATCTTGAAACAACATACCTTGGTATTTCAGCTC
TACTCCTATTTCCGTAGCCGAATGTCTCGTCGTCATACCGATGTAATGATGCTGAGTGAA
CTCAACCAAAAATTGGCCAGAAACATCGAATGGCGACGGTTTTCTATGGATCTGATCCGC
GAACTTCGTCGTCTCTCCGAAGGGAAGGGGAGTGAAGATCTGTTTGTGGTCAATCTCTGG
GGTTATCACTTGACTGTGAAAAGCATTGAAGAGAAAGGCAAAGTGGTGGATTACCAAGTC
GATATCAAATGTGATGTGGAAGAGGTACTGCGCTATTCACGCGCCAAAACCACCAACGCG
GGTAAACGCAATATGGCTCCAACCTTGCCTAACCCTTTACGTAACGAGCTGGTTTCCAAG
CAGAAACTGGCTGAGTTATCGAGCATCATCGATGGTGAATTTGAACCAATCCAGCGCAAA
GCCCCTTCGCCGAGAGGCCGCTTAGGTCGGCGCGTGAAGCTACGTAAACATCTTGTCGAA
ATCAATGCTGATGAAATCACCATTACTCTATCGCGTTATACCTCTCCAGAAGCGCTAGAA
CGCAGTATAACGGCTTTAGCGGCTATGACTGGACACGCCCCTTCATCAATCAAAGAAGAG
TGTGTAGAGCTCATAGACAAGCTAGATTGGCTGCGTGTTGAAAACGATGTGATCCAATAC
CCGACATTGAGCAAGCTGCTTGAGCTCTACAACAGCCAAAATGAGAGTAAACATCTGTCG
ATCGAAAAATTGATCGCAGGTTTAGCGGTACGCCGTAAAGTCTGTAAATTGGTTCAAGAT
GGGCACATTGACGAAACGGTGTATCGAGCCTTAGATGAGATGGCCGCTGGAGCCTAA

# Drug_Target_6_General_Function:
Posttranslational modification, protein turnover, chaperones

# Drug_Target_6_General_References:
10952301	Heidelberg JF, Eisen JA, Nelson WC, Clayton RA, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Umayam L, Gill SR, Nelson KE, Read TD, Tettelin H, Richardson D, Ermolaeva MD, Vamathevan J, Bass S, Qin H, Dragoi I, Sellers P, McDonald L, Utterback T, Fleishmann RD, Nierman WC, White O, Salzberg SL, Smith HO, Colwell RR, Mekalanos JJ, Venter JC, Fraser CM: DNA sequence of both chromosomes of the cholera pathogen Vibrio cholerae. Nature. 2000 Aug 3;406(6795):477-83.

# Drug_Target_6_HGNC_ID:
Not Available

# Drug_Target_6_HPRD_ID:
Not Available

# Drug_Target_6_ID:
6702

# Drug_Target_6_Locus:
Not Available

# Drug_Target_6_Molecular_Weight:
15056.9

# Drug_Target_6_Name:
Organic hydroperoxide resistance protein, putative

# Drug_Target_6_Number_of_Residues:
145

# Drug_Target_6_PDB_ID:
Not Available

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF02566	OsmC

# Drug_Target_6_Protein_Sequence:
>Organic hydroperoxide resistance protein, putative
MRNKNMSTIYQTSATASAGRNGVVSTEDKLLELNLSYPKEMGGSGTATNPEQLFAVGYAA
CFSNAILHVAREAKVALKEAPVTATVGIGPNGQGGFALSVALAAHIALEDEQARQLVTVA
HQVCPYSNAVRGNIDVQVSVNGLAL

# Drug_Target_6_Reaction:
Not Available

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
Not Available

# Drug_Target_6_SwissProt_ID:
Q9KKU4

# Drug_Target_6_SwissProt_Name:
Q9KKU4_VIBCH

# Drug_Target_6_Synonyms:
Not Available

# Drug_Target_6_Theoretical_pI:
6.78

# Drug_Target_6_Transmembrane_Regions:
None

#END_DRUGCARD DB02032
